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Background: Surgery is the standard of care in several oncologic diseases. However, when non-surgical candidates
are not suitable for radical treatment, palliation must be achieved at least. High-intensity focused ultrasound uses
ultrasound power that can be sharply focused for highly localised application, as it is a completely non-invasive
procedure. Its non-invasiveness appears to be of paramount importance in critically ill patients.
Case description: We describe the use of ultrasound-guided high-intensity focused ultrasound for a large liver
metastasis from breast cancer causing gastric outlet obstruction in a metastatic disease. The left liver deposit did
not allow the stomach to empty due to its large volume, and the patient was unable to eat properly. The tumour
was metastatic, resistant to chemotherapy and had a size that contraindicated an ablation percutaneous technique.
To improve the patient's quality of life, ultrasound-guided high-intensity focused ultrasound ablation seemed the
only and most suitable option. Therefore, a high-intensity focused ultrasound treatment was performed, no
complications occurred and the patient's general condition has improved since the early post-procedural period.
Three months after treatment, two body mass index points were gained, and the lesion decreased by 72% in
volume as detected through multi-detector computed tomography follow-up.
Discussion and conclusion: Quality of life is an unquestionable goal to achieve, and palliation must be achieved
while causing as little harm as possible. In this view, debulking surgery and percutaneous ablation technique
seemed not appropriate for our patient. Instead, high-intensity focused ultrasound combined several advantages,
no lesion size limit and a totally non-invasive treatment. Thus, this technique proved to be a clinically successful
procedure, offering better disease control and quality of life. In circumstances where other alternatives clearly seem
to fail or are contraindicated, high-intensity focused ultrasound can be used and can provide benefits. We
recommend its use and development in several oncologic diseases, not only for therapeutic purposes but also for
the improvement of patient's quality of life.
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Surgery is the standard of care for selected patients with
solid tumours of the liver, offering the chance of a
complete cure by tumour removal. Unfortunately, the
majority of patients are unfit for surgical resections be-
cause of the sites of their tumour, advanced disease or
poor general condition. Clinicians have been trying to
develop new standards of care in these circumstances,
such as radiofrequency ablation, percutaneous ethanol
injection, cryoablation, microwave coagulation, laser-
induced interstitial thermotherapy and, finally, high-
intensity focused ultrasound (HIFU).
HIFU uses ultrasound power that can be sharply fo-
cused for highly localised application, as it is a com-
pletely non-invasive procedure. The liver is one of the
first areas where focused ultrasounds have been used
[1]. Several groups have used ultrasound-guided high-
intensity focused ultrasound (USgHIFU) to treat hepatic
neoplasms including primary neoplasms [2,3] or second-
ary deposits [4], regardless of tumour location [5,6].
HIFU non-invasiveness appears to be of paramount
importance in critically ill patients at very high risk for
surgery. Moreover, in addition to the advantage gained
from a curative point of view, HIFU may improve qual-
ity of life, reducing or eliminating tumour-related pain
and providing a debulking of large neoplastic lesions
[7-10]. The case we describe is primarily related to the
improvement of quality of life for a large liver metastasis
causing gastric outlet obstruction in metastatic disease.Figure 1 CT of patient before treatment. (a) Contrast-enhanced
multi-detector CT. A 10 cm × 7 cm liver lesion (blue arrows with
main diameters) completely occupying the left lobe in a multi-
deposit disease is compressing and dislocating the stomach (red
arrows). (b) 3D rendering image pre-treatment.Case description
A 49-year-old female with previously diagnosed breast
cancer was referred to us with metastasis, bilaterally and
extensively in the lung, in the left acetabulum and in the
liver, primarily in the left lobe and in the right (segments 5
to 8 and segment 8, respectively). Three years previously,
she had undergone a wide excision and axillary lymph
node dissection for a ductal carcinoma pT3N1M0. After
the surgery, she was treated with an adjuvant radio-
therapy regimen of 50 GY in 25 fractions over 5 weeks
and first line chemotherapy agents, such as anthra-
cyclines, taxanes (docetaxel) and cyclophosphamide.
She completed a long course of endocrine therapy with
tamoxifen.
Initially, she was started on a monoclonal antibody
therapy with bevacizumab. The disease progressed not-
withstanding the chemotherapy treatment.
The patient, with a KPS of 70%, presented with an-
orexia, right upper quadrant pain, weight of loss body
mass index (BMI) of 16, vomiting and right coxalgia. A
full-body CT scan showed multiple liver and lung de-
posits, and an osteolytic metastases of the left aceta-
bulum (Figure 1a). A 3D rendering of the pre-HIFUreconstruction clearly showed the extent of the disease
(Figure 1b).
The gastric outlet obstruction was due to a left liver
metastasis with a volume of 10 cm × 7 cm × 10 cm, cor-
responding to 365,6993 cm3. The lesion volume was cal-
culated by a volumetric semi-automatic segmentation
technique analysis on CT scan with slices of 2 mm thin.
This lesion caused the most severe symptom upon refer-
ral, compressing the duodenum and delaying gastro-
intestinal transit. Pre-treatment oesophagogastroduode
noscopy confirmed an external obstruction with normal
gastric mucosa. To improve patient's quality of life ef-
fectively without harm, an HIFU procedure seemed to
be the most feasible option for debulking.
HIFU technique
Informed consent was obtained from the patient, and ap-
proval was gained from Azienda Ospedaliero-Universitaria
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was performed with US, and no gas interference in the
acoustic pathway was discovered (Figure 2).
The day before the procedure, bowel preparations had
been administered from late morning (MOVIPREP®
(Norgine Italia S.r.l., Milan, Italy) - Macrogol 3350/so-
dium sulphate, anhydrous/sodium chloride/potassium
chloride/ascorbic acid/sodium ascorbate plus PANAMIR
V (D.M.G. Italia S.r.l. (Rome, Italy) - simethicone), and
the patient was put on a full liquid diet. The skin overly-
ing the lesion was carefully shaved to avoid any potential
hair interference. General anaesthesia with endotracheal
intubation and mechanical ventilation was performed,
thus permitting control of the pulmonary inflation. So
providing provisional suspension of respiration, it was
possible to match the rate of sonication delivery, keeping
the target tumour within the therapeutic zone. Nonethe-
less, the lesion was partially behind the rib cage.
A degassed water balloon was used to push and com-
press the bowel loops to avoid any unexpected presence
of air in the beam pathway and to provide bowel-
movement control. A nasogastric tube was inserted and
left in place to optimise the acoustic pathway and to
detect any gastric damage. The patient was carefully po-
sitioned in the prone position, placing the skin overlying
the target lesion in contact with the degassed water.
A vertical scanning mode was chosen with a 5-mm
distance between each slice. HIFU ablation was con-
ducted with safe margins of 10 mm within the lesion
using the JC200-HIFU system (Chongqing Haifu-HIFU-
Tech, Chongqing, China). Therapeutic US energy was
produced by a transducer with a diameter of 20 cm, a
focal length of 15 cm and a frequency of 0.8 MHz. The
MyLab70 US imaging device (ESAOTE, Genova, Italy)
was used as a real-time imaging unit, using an integral
central 3.5-MHz diagnostic ultrasound probe located in
the centre of the HIFU transducer. By scanning with the
HIFU beam, the targeted region of each section wasFigure 2 US pre-treatment images. Left liver deposit (blue arrows)
is in the target area, being completely in the centre of the US scan.
There was no gas interference in the acoustic pathway.ablated. This process was repeated on a section-by-sec-
tion basis to achieve complete lesion ablation. Real-time
US scans showed changes in the echogenicity of the
treated regions. Comparing gray-scale changes obtained
on the diagnostic images after each HIFU exposure, we
assessed and monitored the extent of treatment. If any
unexpected residual non-ablated portion of the tumour
was found at the site of the treated lesion, an additional
HIFU ablation was performed. Total time (preparation
and treatment) was 5 h and 30 min. Total treatment
time was 3 h and 58 min, with a sonication time of 1 h
and 19 min; both of these respective times were related
to lesion size and blood supply. The focal peak inten-
sities ranged between 400 and 150 W; however, mainly
higher intensity energies were used. The total ablated
volume was 80% (Figure 3).
The osteolytic metastasis of the left acetabulum was
treated with Cyberknife (Accuray Company, Sunnyvale,
USA) stereotactic radiosurgery. Four CT-guided gold fi-
ducials were positioned percutaneously.
Results
After treatment, the patient started feeding carefully
with clear fluid; 3 days later, she was discharged from
our hospital with no symptoms remaining and on a
semi-liquid diet, with more frequent small meals advised
after at least 2 weeks had passed.
The results were considered to be satisfactory based
on necrotic tissue formation in the lesion as well as pa-
tient clinical signs and symptoms. No ablation-related
complications occurred. Laboratory studies showed nor-
mal liver function tests 24 h after the procedure.
Three months after the procedure, the patient had a
BMI of 18. Two additional points of improvement were
shown by post-procedural multi-detector computed
tomography (MDCT); the lesion hypodensity with the
presence of a residual enhancement rim had decreased
in size by approximately 72% (6 cm × 6 cm × 6.5 cm,Figure 3 US images during the treatment. The yellow lines
represent the focal points treated on a single slice. Repeating this
process on each slice, we achieve a complete lesion ablation.
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hancement persisted, suggesting successful local tumour
control (Figure 4a). A 3D rendering of the post-HIFU
reconstruction clearly showed the disease entity (Figure 4b).
Discussion
The liver is a primary site of metastasis for tumours ori-
ginating at many sites [11], and liver metastasis develops
in approximately half of women with metastatic breast
cancer [12]. Therapies for patients with metastatic breast
cancer include systemic chemotherapy [13], hormone
therapy or both [14]. Immunotherapies, commonly
cyclooxygenase-2 or vascular endothelial growth factor
inhibitors such as bevacizumab [15,16], are gaining wide
acceptance as adjuvant agents in a chemotherapy regi-
men, but not as a standard treatment.
Our patient unfortunately showed disease progres-
sion notwithstanding chemotherapy treatments, suchFigure 4 CT of patient 3 months after treatment. (a).
Contrast-enhanced multi-detector CT. A 6 cm × 6 cm liver lesion
(blue arrows) is identified, showing a decrease in size of 72%. (b) 3D
rendering image post-treatment.as anthracyclines, taxanes (docetaxel), cyclophosphamide,
tamoxifen and monoclonal antibody therapy (bevacizumab).
Quality of life is an unquestionable goal to achieve in
these patients. In our experience, we found that the left
liver metastasis was the cause of an outlet obstruction
syndrome. Palliation must be achieved while causing as
little harm as possible. Thus, surgery plays a role if in-
depth knowledge of non-surgical palliative treatments is
not available. Moreover, surgeons must consider the risk
of potentially shortening or reducing the quality of the
patient's remaining time due to surgical complications
[17,18].
In our experience, HIFU non-invasiveness is of para-
mount importance. In fact US waves can penetrate skin
and tissue layers without causing damage to them,
thereby reaching a target further inside the body [19]. At
the focal point, the clinical effect occurs by the following
two main mechanisms: the thermal effect, wherein tem-
peratures can reach 60°C, with cell death occurring at
56°C for > 1 s [20], and the cavitation-induced cellular
damage mechanical effect which is due to mechanical
stress [21]. Consequently, the target tissue is destroyed
by protein coagulation.
HIFU is gaining increasing interest for the treatment
of solid neoplasms [22]. In recent years, many trials have
been conducted proving the efficacy and feasibility of
HIFU ablation in different clinical applications [23-27].
Liver tumours have been treated when considered as pri-
mary neoplasms [2,3] or secondary deposits [4] regard-
less of tumour location [5,6]. Moreover, in addition to
the advantage gained from a curative point of view,
HIFU may improve quality of life with uterine fibroids
[7], reduce or eliminate tumour-related pain in pancre-
atic cancer [8,9] or provide debulking of large neoplastic
lesions [10].
In our case, a debulking procedure was needed, but
the size of the lesion (10 cm × 7 cm × 10 cm) was a
contraindication to local ablative therapies, such as
radiofrequency ablation [28], percutaneous ethanol in-
jection [29], cryoablation [30], microwave coagulation
[31], and laser-induced interstitial thermotherapy [32].
USgHIFU was our last chance to non-invasively treat
the liver metastasis. HIFU has been shown to provide
ablation of large liver tumours ranging in size from 5
to 12 cm in diameter [33], with the maximum size
reached 4 to 14 cm in diameter and an average diameter
of 8.18 ± 3.37 cm [34]. Almost the entire lesion was ab-
lated in our case (80% of the lesion), with a decrease in
size of approximately 72% at 3 months by MDCT, with
the presence of residual enhancement rim. Our goal was
a palliative debulking, and this goal was achieved here.
No complications were detected in our case; in fact,
outside the focal region, the ultrasound intensity is sub-
stantially lower, thus minimising the risk of unintended
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well tolerated, even in severe conditions [35], and this
result was confirmed by our case.
Conclusions
HIFU proved to be a clinically successful procedure,
offering better disease control and quality of life. The
patient became symptom-free, and no complications
occurred. In circumstances where other alternatives
clearly seem to fail or are contraindicated, HIFU can be
used and provides benefits. We recommend its use and
development in several oncologic diseases, not only for
therapeutic purposes but also for the improvement of
patient's quality of life.
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